Several genetically targeted therapies have also been approved, including pembrolizumab for prostate cancer patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) cancer (Sokolova and Cheng 2020), and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and rucaparib for patients with mutations in DNA repair genes, especially BRCA2 (Marshall et al. 2019). The gene discussed is BRCA2; the disease is cancer.